A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

NCT06686576 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

363

Enrollment

INDUSTRY

Sponsor class

Conditions

Colon Cancer

Interventions

DRUG: QL1706
DRUG: CAPEOX/Capecitabine

Sponsor

Qilu Pharmaceutical Co., Ltd.